zhybrids

The Week Ahead: Damage Control

Dendreon, (DNDN) The negative article today is nothing more, then someone trying to either cover a short position before a big run up in the stock price, hold down the stock for others to buy, or someone trying to cause confusion and doubt in the company, for a self motivated reward.

I believe there are several players out their, trying to put a negative spin on the facts and trying to cast doubt in every retail investors mind. Whatever the case may be, I'd take the gamble, and place a bet on the table, as all odds point in favor including the options for May 2009 for LONGS.

Its very clear the calls are currently outpacing puts 4:1 and as long as they show 22%+ on effectiveness from the control group vs placebo, this looks like a home run, for a major move above $25.00/ share.

2 Years ago DNDN's Share price skyrocketed to around $25 on a positive vote from the FDA's Advisory Panel, as the FDA usually goes along with the vote of its advisory panel. An unexpected rejection of the favorable vote from its panel, made DNDN's share price drop from $24+ a share to below $5.00.

Had the company gone on to get a favorable vote and approval from the FDA for its prostate cancer drug PROVENGE, the stock would have rocketed from the $24+ price tag it had going into the FDA meeting. Which leads me to believe the stock has the potential to trade north of $35.00 + as, that would place a 40% increase from the price at the time the FDA Panel had its positive vote.

I do hold a small long position, and feel 90% confident, this time provenge will be approved and feel the corruption in the FDA will not beable to overcome an approval, as it is now clear, there were some conflicts of interest by some board members of the FDA.

It was clear the negative vote, was partially the cause of a couple individuals who were tied to COMPETITORS of Dendreon.

A CONFLICT OF INTEREST, that became well known after the rejection for Provenge.

This time around, they will have to make the case, for not approving, and it will not be easy at all, now that all the facts are on the table about all of those involved with the process.

LONG DENDREON (DNDN)

Everything I state is my opinion, and should not be used for making an investment decision. Research before investing. Understand the risks involved, when investing in the bio-tech industry.

How Biotech ETFs Are Overcoming Sector’s Troubles

Dendreon, (DNDN) The negative article today is nothing more, then someone trying to either cover a short position before a big run up in the stock price, hold down the stock for others to buy, or someone trying to cause confusion and doubt in the company, for a self motivated reward.

I believe there are several players out their, trying to put a negative spin on the facts and trying to cast doubt in every retail investors mind. Whatever the case may be, I'd take the gamble, and place a bet on the table, as all odds point in favor including the options for May 2009 for LONGS.

Its very clear the calls are currently outpacing puts 4:1 and as long as they show 22%+ on effectiveness from the control group vs placebo, this looks like a home run, for a major move above $25.00/ share.

2 Years ago DNDN's Share price skyrocketed to around $25 on a positive vote from the FDA's Advisory Panel, as the FDA usually goes along with the vote of its advisory panel. An unexpected rejection of the favorable vote from its panel, made DNDN's share price drop from $24+ a share to below $5.00.

Had the company gone on to get a favorable vote and approval from the FDA for its prostate cancer drug PROVENGE, the stock would have rocketed from the $24+ price tag it had going into the FDA meeting. Which leads me to believe the stock has the potential to trade north of $35.00 + as, that would place a 40% increase from the price at the time the FDA Panel had its positive vote.

I do hold a small long position, and feel 90% confident, this time provenge will be approved and feel the corruption in the FDA will not beable to overcome an approval, as it is now clear, there were some conflicts of interest by some board members of the FDA.

It was clear the negative vote, was partially the cause of a couple individuals who were tied to COMPETITORS of Dendreon.

A CONFLICT OF INTEREST, that became well known after the rejection for Provenge.

This time around, they will have to make the case, for not approving, and it will not be easy at all, now that all the facts are on the table about all of those involved with the process.

LONG DENDREON (DNDN)

Everything I state is my opinion, and should not be used for making an investment decision. Research before investing. Understand the risks involved, when investing in the bio-tech industry.

Did Dendreon Play with Fire?

The negative article is nothing more, then someone trying to either cover a short position before a big run up in the stock price, hold down the stock for others to buy, or someone trying to cause confusion and doubt in the company, for a self motivated reward.

I believe there are several players out their, trying to put a negative spin on the facts and trying to cast doubt in every retail investor out their. Whatever the case may be, I'd take the gamble, and place a bet on the table, as all odds point in favor including the options for may 2009 for LONGS. Its very clear the calls are currently outpacing puts 4:1 and as long as they show 22%+ on effectiveness from the control group vs placebo, and this looks like a home run, for a major move above $25.00/ share.

2 Years ago DNDN's Share price skyrocketed to around $25 on a positive vote from the FDA's Advisory Panel, as the FDA usually goes along with the vote of its advisory panel. An unexpected rejection of the favorable vote from its panel, made DNDN's share price drop from $24+ a share to below $5.00.

Had the company gone on to get a favorable vote and approval from the FDA for its prostate cancer drug PROVENGE, the stock would have rocketed from the $24+ price tag it had going into the FDA meeting. Which leads me to believe the stock has the potential to trade north of $35.00 + as, that would place a 40% increase from the price at the time the FDA Panel had its positive vote.

I do hold a small long position, and feel 90% confident, this time provenge will be approved and feel the corruption in the FDA will not beable to overcome an approval, as it is now clear, there were some conflicts of interest by some board members of the FDA.

It was clear the negative vote, was partially the cause of a couple individuals who were tied to COMPETITORS of Dendreon.

A CONFLICT OF INTEREST, that became well known after the rejection for Provenge.

This time around, they will have to make the case, for not approving, and it will not be easy at all, now that all the facts are on the table about all of those involved with the process.

LONG DENDREON (DNDN)

Everything I state is my opinion, and should not be used for making an investment decision. Research before investing. Understand the risks involved, when investing in the bio-tech industry.

The Ten Most Promising Net Cash Stocks

ATHX / NEW SEC FILINGS / INSIDERS ARE BUYING NOW March 2009.
Just Announced .
finance.yahoo.com/q/it...


INSIDER TRANSACTIONS REPORTED - LAST TWO YEARS
Date Insider Shares Type Transaction Value*
17-Mar-09 SHEFFERY MICHAEL BDirector 110,000 Indirect Purchase at $0.84 per share. $92,400
17-Mar-09 ORBIMED ADVISORS LLCDirector 110,000 Indirect Purchase at $0.84 per share. $92,400
16-Mar-09 SHEFFERY MICHAEL BDirector 52,200 Indirect Purchase at $0.65 per share. $33,930
16-Mar-09 ORBIMED ADVISORS LLCDirector 52,200 Indirect Purchase at $0.65 per share. $33,930
16-Mar-09 VAN BOKKELEN GILOfficer 10,000 Direct Purchase at $0.67 per share. $6,700

The Ten Most Promising Net Cash Stocks

ATHX Trades at like 50 Cents on the $1.00 Just on Cash Alone. ZERO DEBT / Book Value About $1.70

ATHX .. $1.50 in Cash per share and trading at .75 Cents. Zero Long term Debt and a huge Stem cell Pipeline.....

How can a stock with a pipeline and $1.50 in cash per every share outstanding and ZERO - 0 Long term Debt, trade at less than their cash.

Trading at .75 Cents. Does this make any sense..

Can some of you , who understand financials .. Explain this to me....

I have a Masters in Finance, and I still dont get it....

Its like buying a $1.00 Bill for .50 Cents , as this is approximately 50% of their cash value.........


Anyone else have a stock trading at 50% Below Cash and 0 Debt...

Cause, I dont see too many of these come around. Especially in the biotech / stem cell sector.....

Comments welcomed.

Balance Sheet
Total Cash (mrq): 28.01M
Total Cash Per Share (mrq): 1.48
Total Debt (mrq): 0
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 12.577
Book Value Per Share (mrq): 1.668



Share Statistics
Average Volume (3 month)3: 157,118
Average Volume (10 day)3: 87,912.5
Shares Outstanding5: 18.93M
Float: 12.71M
% Held by Insiders1: 23.09%
% Held by Institutions1: 29.10%

The Ten Most Promising Net Cash Stocks

ATHX / NEW SEC FILINGS / INSIDERS ARE BUYING NOW March 2009.
Just Announced .
finance.yahoo.com/q/it...


INSIDER TRANSACTIONS REPORTED - LAST TWO YEARS
Date Insider Shares Type Transaction Value*
17-Mar-09 SHEFFERY MICHAEL BDirector 110,000 Indirect Purchase at $0.84 per share. $92,400
17-Mar-09 ORBIMED ADVISORS LLCDirector 110,000 Indirect Purchase at $0.84 per share. $92,400
16-Mar-09 SHEFFERY MICHAEL BDirector 52,200 Indirect Purchase at $0.65 per share. $33,930
16-Mar-09 ORBIMED ADVISORS LLCDirector 52,200 Indirect Purchase at $0.65 per share. $33,930
16-Mar-09 VAN BOKKELEN GILOfficer 10,000 Direct Purchase at $0.67 per share. $6,700

Oil Looks Toppy: Ultrashort Oil and Gas Looks Good

Also, If oil does continue to rise, its easy for dug to go up...What happened on May 21,2008, was Oil rose over $4 bucks a barrel to around $134/ barrel and DUG Closed Up almost 3% for the day.
Why? The bear rally is over. We are selling off as I suggested would happen. Yesterday I said financials first, then techs, last commodities.
Oil is going up rapidly and now scaring all players including oil longs
Markets move on perception. That is why financials and retailers did well the past month, with no facts, just perception that things will get better soon. The perception on oil going up so quickly is that this will take down not only the U.S. but all economies remember it's perception.
“We live globally, we die globally.”
The market should continue it's decline if oil continues it's rapid climb. At some point down the road, the bubble will burst. I think this bubble will pop sooner than later and Dug would be a great trade to take advantage of a correction. High oil is a double edged sword if you get my drift.

Dug shareholders objective, we are not looking for a decline in oil, we are looking for a decline in oil and gas stocks.

Also note, as the markets crash lower on higher and higher oil prices money will flow out of consumer cyclicals including financials, tech, and retail; which will lead to a fall in the ^DJUSEN Dow Jones US Energy Index as money will be taken out of winning trades to make up for losses in other sectors.

Once again leading to a drop in the energy stocks.